Wynder Given The American Cancer Society Award at AACR

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 6
Volume 7
Issue 6

NEW ORLEANS--Ernst L. Wynder, MD, DSc, Dr.med.h.c., has received the seventh AACR American Cancer Society Award. Dr. Wynder is president and medical director of the American Health Foundation in New York.

NEW ORLEANS--Ernst L. Wynder, MD, DSc, Dr.med.h.c., has received the seventh AACR American Cancer Society Award. Dr. Wynder is president and medical director of the American Health Foundation in New York.

The award, given yearly to honor research accomplishments in cancer epidemiology, biomarkers, and prevention, was presented at the 89th annual meeting of the American Association for Cancer Research (AACR).

Dr. Wynder was chosen for this year’s award because he was the first scientist in the United States to demonstrate the link between smoking and lung cancer.

At the award presentation, Anna D. Barker, PhD, president and CEO of OXIS International, Portland, Oregon, described how Dr. Wynder began his research while still a medical student. He went to 50 hospitals to interview 684 people with lung cancer and 1,332 controls about their smoking history. This survey established that only eight of the lung cancer patients did not smoke.

Results Published in 1950

Dr. Wynder published his results jointly with surgeon Ewarts Graham, MD, in 1950 in the Journal of the American Medical Association, but it took years for these results to be accepted.

Since that seminal article in 1950, Dr. Wynder has published more than 750 papers. He helped show that smoking also causes cancer of the mouth, larynx, pharynx, and esophagus, and leads to an increased risk for cancer of the pancreas, kidney, and bladder. He also established the American Health Foundation, an institute devoted to research on cancer causation and prevention.

Michael Thun, MD, vice president for epidemiology and surveillance research of the American Cancer Society, presented the award to Dr. Wynder. "He’s a pioneer in the tobacco wars," Dr. Thun said. "He has been way ahead of his time in recognizing the importance of different disciplines working together."

Recent Videos
Further optimizing a PROTAC that targets MDM2 may lead to human clinical trials among patients with cancer harboring p53 mutations.
As patients are nearing the end of life, different management strategies, such as opioids, may be needed to help mitigate pain or fatigue.
Kelley A. Rone, DNP, RN, AGNP-c, highlights the importance of having end-of-life discussions early in a patient’s cancer treatment course.
Patients treated with BCMA-directed immunotherapies for myeloma may experience susceptibility to severe infections following treatment.
4 KOLs are featured in this series.
4 KOLs are featured in this series.
4 KOLs are featured in this series.
4 KOLs are featured in this series.
Related Content